SOURCE: SciClone Pharmaceuticals, Inc.

SciClone Pharmaceuticals, Inc.

November 23, 2009 07:00 ET

SciClone Pharmaceuticals to Present at the Piper Jaffray Annual Healthcare Conference

FOSTER CITY, CA--(Marketwire - November 23, 2009) - SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it will present at the upcoming Piper Jaffray Annual Healthcare Conference in New York City. Friedhelm Blobel, Ph.D., SciClone's President and Chief Executive Officer, will present a corporate overview and business update on Tuesday, December 1, 2009 at 11:00 am ET.

To access the live audio webcasts of the presentations, please log on through a link located in the Investor Relations section of SciClone's website at

About SciClone

SciClone Pharmaceuticals (NASDAQ: SCLN) is a profit-driven, global specialty pharmaceutical company with a substantial international business and a product portfolio of novel therapies for cancer and infectious diseases. SciClone is focused on continuing international sales growth, a cost-containing clinical development strategy, and overall expense management. ZADAXIN® (thymalfasin or thymosin alpha 1) is sold in over 30 countries for the treatment of hepatitis B (HBV) and hepatitis C (HCV), certain cancers and as a vaccine adjuvant. SciClone's pipeline of drug candidates includes thymalfasin, in preclinical studies as an enhancer of H1N1 flu vaccines; thymalfasin for stage IV melanoma, for which SciClone has reached agreement with the FDA on the design of a phase 3 trial; SCV-07 in a phase 2 trial for the delay of onset of severe oral mucositis in patients receiving chemoradiation therapy for the treatment of cancers of the head and neck; and SCV-07 in a phase 2 trial for the treatment of HCV. SciClone has exclusive commercialization and distribution rights to DC Bead™ in China, where the product is under regulatory review. The Company also has exclusive commercialization and distribution rights to the anti-nausea drug ondansetron RapidFilm™ in China and Vietnam, for which it will seek regulatory approval. For additional information, please visit